CD19 and acute lymphoblastic leukemia: CAR-T cell products targeting the cell surface protein CD19 are commercially available for treatment of relapsed and/or refractory (R/R) B cell non-Hodgkin lymphomas (NHLs) (3–6) and acute lymphoblastic leukemia (ALL) (7).